Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA's Overreach on Compounded Peptides Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction